

# CIPRO-CENT

## Composition

Each ml of **CIPRO-CENT Eye/Ear Drops** contains:

Ciprofloxacin hydrochloride equivalent to ciprofloxacin 0.3% w/v

## Pharmacology

**CIPRO-CENT** contains the potent fluoroquinolone antibacterial ciprofloxacin. It acts by inhibiting bacterial DNA gyrase, so preventing the super-coiling of DNA, a process that is necessary for compacting chromosomes into the bacterial cell.

**CIPRO-CENT** is bactericidal. Ciprofloxacin acts against a wide range of Gram-negative and Gram-positive organisms including *Haemophilus influenzae*, *Pseudomonas aeruginosa*, *Serratia marcescens*, *Niesseria gonorrhoea*, *Staphylococcus aureus* (including methicillin-susceptible and methicillin-resistant strains), *Staphylococcus epidermidis*, *Streptococcus pneumoniae* and other species of *Streptococcus*.

On topical application of **CIPRO-CENT** the maximum reported plasma concentration of ciprofloxacin was less than 5 ng/ml. The mean concentration was usually less than 2.5 ng/ml

## Indications

**CIPRO-CENT Eye Drops** are indicated for the treatment of:

- Conjunctivitis
- Corneal ulcers
- Hypopyon ulcer
- Superficial and deeper eye infections
- Pre and post-operative care

**CIPRO-CENT Ear Drops** are indicated for the treatment of chronic suppurative otitis media and mastoiditis.

## Contraindications

A history of hypersensitivity to ciprofloxacin or any other component of the medication is a contraindication to its use. A history of hypersensitivity to other quinolones may also contraindicate the use of **CIPRO-CENT**.

## Precautions

As with other antibacterial preparations, prolonged use of **CIPRO-CENT** may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, appropriate therapy should be initiated. Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis.

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolone therapy.

### **Pregnancy & Lactation**

There are no adequate and well-controlled studies in pregnant women. **CIPRO-CENT** should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus.

It is not known whether topically applied ciprofloxacin is secreted in milk. Therefore, caution should be exercised when **CIPRO-CENT** is administered to a nursing mother.

### **Drug Interactions**

Specific drug interaction studies have not been conducted with ophthalmic ciprofloxacin. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, enhance the effects of the oral anticoagulant, warfarin, and its derivatives and has been associated with transient elevations in serum creatinine in patients receiving cyclosporin concomitantly.

### **Adverse Reactions**

The most frequently reported drug related adverse reaction with ciprofloxacin is local burning or discomfort. Other reactions occurring in less than 10% of patients include lid margin crusting, crystals/scales, foreign body sensation, itching, conjunctival hyperemia and taste disturbances following instillation.

### **Dosage & Administration**

The recommended dosage regimen for the treatment of corneal ulcers is two drops of **CIPROCENT Eye/Ear Drops** into the affected eye every 15 minutes for the first six hours and then two drops into the affected eye every 30 minutes for the remainder of the first day. Treatment may be continued after 14 days if corneal re-epithelialization has not occurred.

The recommended dosage regimen for the treatment of bacterial conjunctivitis is one or two drops of **CIPROCENT Eye/Ear Drops** into the conjunctival sac(s) every two hours while awake for two days and one or two drops every four hours while awake for the next five days.

### **Presentation**

**CIPROCENT Eye/Ear Drops** are available in a 5 ml lupolen vial.